Baseline FeNO Independently Predicts the Dupilumab Response in Patients With Moderate-to-Severe Asthma
Ian Pavord(Oxford BioMedica (United Kingdom)), William W. Busse(University of Wisconsin–Madison), Jonathan Corren(California Allergy and Asthma Medical Group), Nadia Daizadeh, Michel Djandji(Sanofi (France)), Nora Crikelair(Regeneron (United States)), Thomas B. Casale(University of South Florida), Sivan Harel, J Mark FitzGerald(University of British Columbia), Kenji Izuhara(Saga Medical School Hospital), Paul J. Rowe(Sanofi (United States)), Robert R. Johnson(Azienda Ospedaliera San Giovanni Addolorata), Ledia Goga(Sanofi (France)), Yamo Deniz(Regeneron (United States)), Benjamin Ortiz(Harlem Hospital Center)
The Journal of Allergy and Clinical Immunology In Practice
December 16, 2022
Cited by 94
Related Papers
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines—2016 revision
|Journal of Allergy and Clinical Immunology|2017|2k
An Official American Thoracic Society/European Respiratory Society Statement: Asthma Control and Exacerbations
|American Journal of Respiratory and Critical Care Medicine|2009|1.9k
Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 Revision
|Journal of Allergy and Clinical Immunology|2010|1.8k
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
|Journal of Allergy and Clinical Immunology|2001|1.3k